Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of "Moderate Buy" from Analysts
Lantheus Holdings, Inc. (NASDAQ:LNTH) has received a "Moderate Buy" rating from analysts, with eight brokerages offering an average one-year price target of $78.00. The company has recently seen significant institutional buying, with M&T Bank Corp and Farallon Capital Management LLC increasing their stakes, bringing institutional ownership to approximately 99.06%. Lantheus's stock performance indicates recent upward momentum, trading at $71.27 with a market capitalization of $4.73 billion.
TD Cowen Updates Financial Model Citing Upcoming Q4 Results for Lantheus Holdings, Inc. (LNTH)
TD Cowen has updated its financial model for Lantheus Holdings, Inc. (LNTH) and lowered its price target to $75 from $80, while maintaining a Buy rating, in anticipation of the company's upcoming fourth-quarter results. This follows Lantheus's recent divestiture of its SPECT business to SHINE Technologies, a strategic move aimed at focusing on PET radiodiagnostics and microbubble products for future growth. The company, recognized as a leader in radiopharmaceuticals, plans to continue investing in its pipeline to develop novel diagnostic and therapeutic solutions.
Assetmark Inc. Purchases 19,844 Shares of Lantheus Holdings, Inc. $LNTH
Assetmark Inc. increased its stake in Lantheus Holdings, Inc. by 20.1% during the third quarter, now holding 118,503 shares valued at approximately $6.08 million. Institutional investors collectively own about 99.06% of Lantheus, which has a market cap of $4.6 billion and a "Moderate Buy" analyst consensus with an average price target of $78.00. The company's stock trades within a 12-month range of $47.25 to $111.29 and has a current P/E ratio of 29.15.
LSV Asset Management Sells 207,400 Shares of Lantheus Holdings, Inc. $LNTH
LSV Asset Management significantly reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 73.1% in the third quarter, selling 207,400 shares and retaining 76,400 shares valued at approximately $3.92 million. Despite this reduction, other institutional investors increased or initiated positions, with institutional ownership nearing 99.06%. Analyst sentiment for Lantheus remains largely positive with a "Moderate Buy" consensus and an average price target of $78.00.
Lantheus Holdings, Inc. $LNTH Shares Acquired by Illinois Municipal Retirement Fund
The Illinois Municipal Retirement Fund significantly increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 88.1% in the third quarter of last year, acquiring an additional 28,138 shares to own a total of 60,067 shares valued at approximately $3.08 million. Other institutional investors like Assenagon Asset Management, Polaris Capital Management, and Norges Bank also acquired new stakes, bringing institutional ownership of the stock to 99.06%. Lantheus, a global life sciences company focusing on diagnostic imaging and radiopharmaceuticals, maintains a "Moderate Buy" rating from analysts with an average target price of $78.
Q1 Earnings Estimate for Lantheus Issued By Brookline Cap M
Brookline Cap M issued Q1 earnings estimates for Lantheus Holdings, Inc. (NASDAQ:LNTH), forecasting $1.03 EPS, with Q2 at $1.08 EPS and FY2026 at $4.68 EPS, notably below the consensus of $6.01. Despite this lower estimate, other analysts like Mizuho and Truist have raised their price targets and ratings, contributing to a "Moderate Buy" consensus for the stock. Institutional investors hold a significant portion of Lantheus shares, which currently trade with a market capitalization of $4.60 billion.
Understanding the Setup: (LNTH) and Scalable Risk
This article provides an in-depth analysis of Lantheus Holdings Inc. (NASDAQ: LNTH), noting a potential shift in positive near-term sentiment and an ongoing breakout. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also includes multi-timeframe signal insights, highlighting support and resistance levels.
Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. announced it will host a conference call and webcast on Thursday, February 26, 2026, at 8:00 a.m. ET to discuss its financial and operating results for the fourth quarter and full year of 2025. Interested participants can register online via the company's investor relations website, with a replay available after the webcast. Lantheus is a radiopharmaceutical-focused company specializing in therapies to find, fight, and follow diseases.
Leerink Partners raises Lantheus stock price target to $94 on growth outlook
Leerink Partners has increased its price target for Lantheus Holdings (NASDAQ:LNTH) to $94 from $90, reaffirming an Outperform rating ahead of the company's Q4 earnings. The firm anticipates investor focus on the stabilization of Pylarify's competitive dynamics and foresees underappreciated tailwinds with 2026 catalysts, including new revenue streams from upcoming PDUFAs. Lantheus is also highlighted for its "GREAT" financial health, strong cash flow, and 13 additional investment tips identified by InvestingPro.
Leerink Partners raises Lantheus stock price target to $94 on growth outlook
Leerink Partners has increased its price target for Lantheus Holdings (NASDAQ:LNTH) from $90.00 to $94.00, maintaining an Outperform rating ahead of its Q4 earnings report. The firm anticipates investor focus on the stabilization of Pylarify's competitive dynamics and foresees underappreciated tailwinds and catalysts in 2026, including new revenue streams from three potential PDUFAs. Financial health data from InvestingPro indicates Lantheus is undervalued, boasts strong cash flows, and has a "GREAT" financial health score, with the price target increase reflecting improved trends for Pylarify volume growth and new product progression.
Waterfront Wealth Inc. Buys Shares of 18,518 Lantheus Holdings, Inc. $LNTH
Waterfront Wealth Inc. has acquired a new stake of 18,518 shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the third quarter, valued at approximately $950,000. This purchase contributes to the 99.06% institutional ownership of Lantheus, with several other institutions also increasing their positions. Wall Street analysts have shown increased optimism for Lantheus, with a consensus "Moderate Buy" rating and a target price of $78.00, following strong Q3 earnings where the company met EPS estimates and exceeded revenue expectations.
Lantheus Holdings, Inc. $LNTH Stake Cut by Homestead Advisers Corp
Homestead Advisers Corp significantly reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 49.7% in the third quarter, selling 28,900 shares, though institutional ownership remains high at 99.06%. Despite this stake cut, analyst sentiment for Lantheus is largely positive, with a "Moderate Buy" consensus rating and an average price target of $78.00. The company reported strong Q3 earnings, meeting EPS estimates and exceeding revenue expectations.
Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lantheus Holdings, Inc. (LNTH) securities. The firm encourages stockholders who purchased Lantheus securities prior to November 6, 2024, and still hold them, to contact them to assist in the investigation into possible corporate wrongdoing by the company and its officers/directors. The firm operates on a contingency fee basis, meaning investors incur no out-of-pocket expenses unless successful.
Strs Ohio Decreases Position in Lantheus Holdings, Inc. $LNTH
Strs Ohio significantly reduced its stake in Lantheus Holdings, Inc. by 91.2% in Q3, selling 40,300 shares and retaining 3,900 shares worth $200,000. Despite this reduction, analysts maintain a "Moderate Buy" rating for Lantheus with an average price target of $78.00. The company reported Q3 EPS of $1.27 and revenue of $384.0M, exceeding revenue estimates, but setFY2025 EPS guidance below analyst expectations.
Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring a 24.72% Upside Potential in the Healthcare Sector
Lantheus Holdings, Inc. (LNTH) is a healthcare company focused on diagnostic and therapeutic products for various diseases, boasting a market capitalization of $4.55 billion. Analysts maintain a bullish outlook with 11 'Buy' ratings and an average target price of $83.46, suggesting a 24.72% upside from its current trading price. The company shows solid financial health with a robust Return on Equity and significant free cash flow, alongside continuous product innovation and strategic collaborations.
Federated Hermes Inc. Sells 101,286 Shares of Lantheus Holdings, Inc. $LNTH
Federated Hermes Inc. has significantly reduced its stake in Lantheus Holdings, Inc. by 35.3%, selling 101,286 shares and retaining 185,462 shares valued at approximately $9.51 million. Despite this sale, analysts maintain a "Moderate Buy" rating for Lantheus with a consensus target price of $78.00, following several price target raises and upgrades. Lantheus recently met its EPS estimates and surpassed revenue expectations for the last quarter, also providing strong FY2025 guidance.
Keybank National Association OH Sells 327,696 Shares of Lantheus Holdings, Inc. $LNTH
Keybank National Association OH significantly reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by selling 327,696 shares, decreasing its position by 63.7% in the third quarter. Despite this, Lantheus reported Q3 earnings that met estimates ($1.27 EPS) and revenue that beat expectations ($384.01 million), also providing strong FY2025 guidance. The stock maintains a "Moderate Buy" consensus rating from analysts, with updated price targets.
We Think Lantheus Holdings (NASDAQ:LNTH) Can Stay On Top Of Its Debt
Lantheus Holdings (NASDAQ:LNTH) utilizes debt but appears to manage it comfortably. With a net debt of US$185.3m and a strong cash reserve, the company's low debt to EBITDA ratio and positive interest income suggest a healthy financial position. While EBIT saw a 28% decrease, its strong free cash flow generation enables effective debt reduction, indicating the company's ability to maintain its debt obligations despite some profitability concerns.
Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. – LNTH
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into Lantheus Holdings, Inc. (NasdaqGM: LNTH) concerning potential breaches of fiduciary duties by its officers and directors. This investigation follows a securities class action lawsuit filed against Lantheus after the company reported an 8% decline in its Pylarify product revenue and cut full-year guidance in August 2025, contrary to earlier optimistic forecasts. The lawsuit alleges that the company failed to disclose material information regarding unreliable forecasting processes and underestimation of pricing risks related to a CMS rule change.
Mutual of America Capital Management LLC Cuts Stock Position in Lantheus Holdings, Inc. $LNTH
Mutual of America Capital Management LLC reduced its stake in Lantheus Holdings, Inc. (LNTH) by 27.8% in the third quarter, selling 21,576 shares. Despite this, other institutions like Assenagon Asset Management, Polaris Capital Management, and Norges Bank significantly increased their positions, indicating strong institutional interest with 99.06% ownership. Lantheus reported Q3 EPS in line with estimates and revenue above consensus, and analysts have a "Moderate Buy" rating with a $78 price target.
Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH
Kahn Swick & Foti, LLC (KSF) has launched an investigation into Lantheus Holdings, Inc. (LNTH) and its officers and directors. This follows an 8% year-over-year decline in revenue for their flagship product, Pylarify, cuts to full-year guidance, and a securities class action lawsuit alleging failure to disclose material information regarding unreliable forecasting and underestimated pricing/reimbursement risks. KSF is examining whether Lantheus’s officers and directors breached fiduciary duties or violated laws, and is seeking information from long-term shareholders.
Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH
Kahn Swick & Foti, LLC (KSF) has launched an investigation into the officers and directors of Lantheus Holdings, Inc. (LNTH). This investigation follows a securities class action lawsuit against the company, which alleges that Lantheus failed to disclose material information regarding the growth potential of its product Pylarify and its forecasting reliability, particularly concerning changes in Medicare & Medicaid Services reimbursement rules. KSF is seeking information from long-term shareholders regarding potential breaches of fiduciary duties or violations of state and federal laws.
The Truth About Lantheus Holdings Inc: Why Wall Street Is Quietly Losing It Over LNTH
This article examines Lantheus Holdings Inc (LNTH), a diagnostic imaging and radiopharma company, highlighting its quiet but significant presence on Wall Street despite not being a mainstream trend. It discusses the company's potential as a future game-changer in healthcare due to its specialized products and strong business fundamentals, while also acknowledging risks such as regulation and competition. The piece concludes that LNTH is a serious consideration for long-term investors interested in medical imaging and precision diagnostics.
Lantheus Holdings, Inc. (LNTH): Analyst Consensus Reveals a Robust 24.2% Potential Upside
Lantheus Holdings, Inc. (LNTH) is a healthcare company focused on diagnostic and therapeutic products with a strong analyst consensus indicating a 24.2% potential upside. Despite flat recent performance, analysts rate it highly with 11 "Buy" and two "Hold" recommendations, and no "Sell" ratings. The company showcases solid financial health with a 14.59% ROE and significant free cash flow, along with innovative products and key industry collaborations.
Y Intercept Hong Kong Ltd Purchases New Shares in Lantheus Holdings, Inc. $LNTH
Y Intercept Hong Kong Ltd has acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH), purchasing 75,382 shares valued at approximately $3.87 million during Q3, representing about 0.11% of the company. Other institutional investors like Assenagon Asset Management S.A. and Polaris Capital Management LLC also increased their positions, bringing institutional ownership to 99.06%. Lantheus met its Q3 EPS expectations, exceeded revenue estimates, and analysts maintain a "Moderate Buy" rating with a consensus price target of $78.00.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Lantheus Holdings, Inc. (LNTH) for alleged corporate wrongdoing. The firm encourages stockholders who purchased Lantheus securities before November 6, 2024, and still hold them, to contact them to assist with the investigation. This investigation aims to restore investor capital and ensure corporate accountability.
Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of "Moderate Buy" from Analysts
Lantheus Holdings, Inc. (NASDAQ:LNTH) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $78.00. The company recently reported strong quarterly earnings, beating revenue estimates, and shows solid profitability with a net margin of 10.99% and a return on equity of 30.88%. Institutional investors own a significant portion of the company's stock.
Precision Trading with Lantheus Holdings Inc. (LNTH) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Lantheus Holdings Inc. (LNTH), identifying its current market sentiment as positive but potentially shifting, with elevated downside risk. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to guide traders on entry and exit points.
First National Advisers LLC Cuts Stake in Lantheus Holdings, Inc. $LNTH
First National Advisers LLC significantly reduced its stake in Lantheus Holdings, Inc. by 71.7% in Q3, selling over 20,000 shares. Despite this, other institutional investors increased their holdings. Lantheus reported Q3 EPS in line with estimates and revenue above expectations, while analysts maintain a "Moderate Buy" rating with an average target price of $78.
Long-Term Investors in Lantheus Holdings, Inc. (NASDAQ: LNTH)
The Shareholders Foundation has initiated an investigation on behalf of long-term investors in Lantheus Holdings, Inc. (NASDAQ: LNTH) concerning potential breaches of fiduciary duties by the company's directors and officers. This follows a lawsuit alleging that Lantheus made misleading statements and concealed material adverse facts regarding Pylarify's competitive position, particularly concerning a price increase that created opportunities for competitors. Current long-term investors are encouraged to contact the Shareholders Foundation for options regarding the ongoing investigation.
Polaris Capital Management LLC Invests $32.69 Million in Lantheus Holdings, Inc. $LNTH
Polaris Capital Management LLC recently invested $32.69 million in Lantheus Holdings, Inc. (NASDAQ:LNTH), acquiring 637,300 shares, making it their 21st largest position. Lantheus reported strong Q3 earnings, exceeding revenue estimates, and analysts maintain a "Moderate Buy" rating with a consensus price target of $78. Other institutional investors have also adjusted their stakes in the medical equipment provider.
Lantheus Holdings, Inc. (LNTH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Lantheus Holdings, Inc. (NASDAQ:LNTH). The firm encourages investors who bought Lantheus securities before November 6, 2024, and still hold them, to contact them to learn more and assist with the investigation. The firm operates on a contingency fee basis for class action lawsuits.
Technical Reactions to LNTH Trends in Macro Strategies
This article analyzes Lantheus Holdings Inc. (LNTH) using AI models to provide trading strategies. It identifies near-term weak sentiment, mid-term strength, and a broader long-term weak bias, offering specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies. The analysis also details multi-timeframe signal strengths, support, and resistance levels for the stock.
The Bull Case For Lantheus (LNTH) Could Change Following SPECT Exit And Neuro Imaging Refocus
Lantheus Holdings has sold its SPECT business unit and focused on neurodegenerative imaging, including upcoming regulatory decisions for new agents and a reformulated Pylarify launch. This strategic shift aims to concentrate resources on high-growth imaging platforms, potentially reshaping investor perspective on the company's product concentration risk versus its innovation pipeline. The company also anticipates a March 2026 approval for reformulated Pylarify, which is central to its short-term thesis and could stabilize prostate cancer imaging economics.
The Bull Case For Lantheus (LNTH) Could Change Following SPECT Exit And Neuro Imaging Refocus
Lantheus Holdings has sold its SPECT business and is concentrating on high-growth neurodegenerative imaging, with anticipated regulatory decisions for new agents in 2026 and a reformulated Pylarify launch. This strategic shift aims to improve product focus and mitigate risks associated with pricing pressures and over-reliance on legacy products. Investors will now need to assess the company's innovation pipeline against its product concentration risk.
LNTH: Lantheus Closes SPECT Sale
Lantheus Holdings, Inc. (NASDAQ:LNTH) has updated investors on recent developments, including the sale of its single photon emission computed tomography (SPECT) business unit at the end of 2025. This divestment aims to refocus resources on its commercialized products and development pipeline. Additionally, new data was presented at the CTAD 2025 conference regarding Neuraceq's interference with Alzheimer's treatments, and financial estimates for 2026 have been refined, leading to a lowered EPS and valuation for the company.
LNTH - Velan Capital Agrees to Support Merger of Lantheus and Progenics
Velan Capital has announced its support for the proposed merger between Lantheus Holdings Inc. (LNTH) and Progenics Pharmaceuticals Inc. (PGNX). Velan, a significant shareholder in both companies, will vote its shares in favor of the merger, which aims to create a combined entity leveraging Lantheus's expertise in manufacturing and commercialization with Progenics' oncology products and pipeline. The agreement follows Velan's successful campaign in 2019 to reconstitute the Progenics Board, which subsequently negotiated the amended merger terms.
LNTH Stock Price, Forecast & Analysis | LANTHEUS HOLDINGS INC (NASDAQ:LNTH)
This article provides an analysis of Lantheus Holdings Inc. (LNTH) stock, including its current price, key statistics, and performance. LNTH specializes in diagnostic imaging and nuclear medicine products, focusing on radiopharmaceutical oncology and precision diagnostics. The company has a current stock price of $67.56, a market cap of $4.48 billion, and has received a ChartMill Technical rating of 7/10 and a Fundamental rating of 7/10.
ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics
Velan Capital has agreed to support the proposed merger between Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. Velan, a significant stockholder in both companies, will vote its shares in favor of the merger, which is based on an amended agreement. This support comes after Velan led a successful consent solicitation at Progenics, resulting in a reconstituted board that ultimately negotiated and recommended the revised merger terms.
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
Lantheus Holdings, Inc. announced a proposed offering of $500 million in convertible senior notes due 2027, with an option for initial purchasers to acquire an additional $75 million. The notes will be senior unsecured obligations, guaranteed by Lantheus Medical Imaging, Inc., and will mature on December 15, 2027. Lantheus plans to use up to $75 million of the net proceeds to repurchase common stock from purchasers of the notes and allocate the remainder for general corporate purposes, including potential acquisitions and debt refinancing.
Stanley Laman Group Ltd. Acquires 22,229 Shares of Lantheus Holdings, Inc. $LNTH
Stanley Laman Group Ltd. has significantly increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 38.7% in the third quarter of 2025, acquiring 22,229 additional shares to now own 79,686 shares valued at approximately $4.09 million. The company, a global life sciences firm specializing in diagnostic imaging and radiopharmaceuticals, currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $78.00. Lantheus has a market capitalization of $4.46 billion and recently reported $0.05 EPS on $92.5 million revenue.
A Look At Lantheus Holdings (LNTH) Valuation After Recent Short Term Share Price Momentum
Lantheus Holdings (LNTH) has recently seen its shares close at $67.27, demonstrating a strong 29.76% return over the past three months, contrasting with a 28.30% decline over the past year. Despite shorter-term momentum, long-term holders are still underwater, raising questions about whether the company is truly undervalued. Analysts suggest an implied fair value of approximately $82.29, with a consensus price target of $89.50, driven by expectations of future earnings growth and profit margins.
Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
Lantheus Holdings, Inc. has finalized the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC. This divestiture allows Lantheus to concentrate on its growing portfolio of PET radiodiagnostics and microbubbles, as well as advancing its radiopharmaceutical pipeline. The sale includes diagnostic agents like TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®, along with related manufacturing and Canadian operations.
Lantheus Closes SPECT Business Sale to SHINE Technologies
Lantheus Holdings, Inc. (NASDAQ: LNTH) has completed the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC. This divestiture includes diagnostic agents, manufacturing facilities, and Canadian operations related to SPECT products. Lantheus plans to focus on its commercial portfolio of innovative PET radiodiagnostics and microbubbles, as well as its pipeline of radiopharmaceuticals.
Lantheus closes SPECT business sale to SHINE Technologies
Lantheus Holdings has completed the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies. This divestiture allows Lantheus to concentrate on its growing commercial portfolio of PET radiodiagnostics and microbubbles, as well as advancing its radiopharmaceutical pipeline. SHINE Technologies acquired Lantheus’ SPECT diagnostic agents, a manufacturing facility in North Billerica, Massachusetts, and the SPECT-related Canadian operations.
Lantheus conclui venda de negócio SPECT para SHINE Technologies
Lantheus Holdings, Inc. (NASDAQ:LNTH) concluiu a venda de seu negócio de tomografia computadorizada por emissão de fóton único (SPECT) para a SHINE Technologies, LLC. Esta alienação permite que Lantheus foque em seu portfólio de radiodiagnósticos PET e microbolhas, buscando inovações na linha de radiofarmacêuticos. A transação incluiu agentes diagnósticos SPECT e uma parte do campus de North Billerica, Massachusetts, dedicado a esses produtos.
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
Lantheus Holdings, Inc. has announced the pricing of $500 million in aggregate principal amount of convertible senior notes due 2027. These notes, sold to qualified institutional buyers, will bear interest at 2.625% per year and mature on December 15, 2027. Lantheus plans to use a portion of the net proceeds to repurchase shares of its common stock and the remainder for general corporate purposes, including potential acquisitions and strategic transactions.
Lantheus Holdings Stock (LNTH) Opinions on SPECT Business Sale
Lantheus Holdings (LNTH) recently completed the sale of its SPECT business to SHINE Technologies, a move discussed on social media as a strategic pivot to streamline its focus on radiopharmaceuticals. Opinions are split, with some seeing the stock as undervalued post-divestiture, while others remain cautious due to broader market uncertainties. Insider trading shows recent sales by executives and significant institutional activity, including major increases and decreases in holdings.
Lantheus Holdings, Inc. Completes Sale of SPECT Business to SHINE Technologies, LLC
Lantheus Holdings, Inc. has divested its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, including diagnostic agents and manufacturing operations. This strategic move allows Lantheus to concentrate on its growing portfolio of PET radiodiagnostics and microbubble products, and advancing its radiopharmaceutical pipeline. The sale enhances Lantheus' focus on innovative diagnostic imaging solutions while streamlining its operations.
LNTH - Lantheus Holding Latest Stock News & Market Updates
Lantheus Holdings (NASDAQ: LNTH) is a radiopharmaceutical company focusing on diagnostic imaging products and a radiopharmaceutical pipeline. Recent news highlights include regulatory milestones for its pipeline, such as FDA acceptance of NDAs for imaging agents and setting PDUFA dates for new products targeting neuroendocrine tumors and Alzheimer’s disease. The company has also been engaged in business development, including acquisitions and divestitures, to shape its portfolio in the medical imaging space.
